Skip to content

Evofem Biosciences, Inc.

About Us
Our Product
- phexxi^®
Publications
Investors
Contact

Side Effects by Frequency of Use with EVO100 Vaginal Gel: Results From The Phase 2B/3 AMPREVENCE Trial.

Post navigation

Previous: Variability in Contraceptive Clinical Trial Design and the Challenges in Making Comparisons Across Trials

Next: Timing of On-Study Pregnancies with a Vaginal pH Modulator in the Phase 3 AMPOWER Trial

Mailing Address:

7770 Regents Road Suite 113-618
San Diego, California 92122
1.858.550.1900

Headquarters:

12636 High Bluff Drive, Suite 400
San Diego, CA 92130

Phexxi^® and the Phexxi logo are registered trademarks of Evofem Biosciences, Inc.
Other trademarks, registered or otherwise, are the property of their respective owner(s).

Quick Links

About Us
Phexxi ^®
Pipeline

Contact

Investor
Media
General
Careers

© 2022 Evofem Biosciences, Inc.

Privacy Policy
Legal
Compliance